HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

ORIC

0.00

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ: ORIC) with a Buy and maintains $25 price target.